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Background: As in the general population, in patients on haemodialysis (HD) hyponatraemia
is  associated with higher mortality risk. The objective of this article was to study the rela-
tionship between predialysis serum sodium (sNa) and mortality in an HD population. We
also  intended to deﬁne hyponatraemia and determine the characteristics of hyponatraemic
patients in terms of anthropometric data, analytical features, dialysis measurements and
hydration (bioimpedance).
Methods: Observational, descriptive study of a cohort of HD incident patients. The indepen-
dent variable was the mean of each patient’s sNa analysed during their ﬁrst 6 months on
HD.
Results: A total of 4153 patients were included in the study. Mean age was 64.7 years; 65.2%
of  the patients were male and 35% were diabetics. Mean follow-up time was 21.48 (SD)
(1.31)  months. sNa had a normal distribution, with a mean (SD) = 138.46 (2.7) mEq/l. Bodyweight, diabetes mellitus, systolic blood pressure, interdialytic weight gain, total ultraﬁl-
se, albumin and creatinine, vascular access and haemodialysis type,tration, serum glucoacquire signiﬁcant differences between sodium quartiles. Lean tissue index (LTI) in patients
with low serum sodium, Q1 (135 mEq/l), was signiﬁcantly lower than the LTI of patients from
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the other serum sodium quartiles. Patients with sNa < 136 mEq/l had a higher independent
mortality risk (OR = 1.62) (Cox regression analysis).
Conclusions: HD patients with hyponatraemia patients have a poor prognosis and present
malnutrition or ﬂuid overload.
© 2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Hiponatremia,  mortalidad  y  hemodiálisis:  una  asociación  no  explicada
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Introducción: Al igual que en la población general, en los pacientes en hemodiálisis (HD),
la  hiponatremia también se asocia a mayor riesgo de muerte. El objetivo de este trabajo es
estudiar en la población en HD la relación entre natremia y mortalidad. Deﬁnir hiponatremia
en  HD y determinar qué peculiaridades tienen los pacientes hiponatrémicos en relación con
aspectos antropométricos, analíticos, dialíticos y de hidratación, mediante bioimpedancia.
Metodos: Estudio observacional, descriptivo, de una cohorte de pacientes incidentes en HD.
La  variable independiente fue la media de las natremias medidas en los 6 primeros meses
en  HD.
Resultados: Se incluyó a 4.153 pacientes. La edad media era de 64,7 an˜os y predominaban
los  hombres con un 64,2%. Un 34,8% eran diabéticos. El tiempo medio de seguimiento fue
21,48 (DE) (1,31) meses. Las natremias tenían una distribución normal, con una media (DE)
de  138,46 (2,7) mEq/l. Las variables que presentan diferencias signiﬁcativas en función de
los  cuartiles de natremia son: peso, diabetes, presión arterial sistólica, ganancia de peso
interdialítica, ultraﬁltración total, glucemia, albúmina y creatinina séricas y tipo de acceso
vascular y de HD.
El índice de masa magra (LTI) en los pacientes con hiponatremia, Q1 (135 mEq/l), fue signi-
ﬁcativamente más bajo que el del resto de pacientes. Los pacientes con una natremia menor
de  136 mEq/l tienen un riesgo independiente de mortalidad mayor que el resto (OR = 1,62)
(análisis de regresión de Cox).
Conclusiones: Los pacientes en HD con hiponatremia tienen mal pronóstico y presentan
desnutrición o sobrecarga de volumen.
© 2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
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yponatraemia, a blood sodium (Na) level under 135 mmol/l,
s a common electrolyte disorder that is associated with high
ortality in the general population.1–3 This poor prognosis
ssociated with hyponatraemia is more  pronounced in cer-
ain populations: women, post-operative patients, cirrhotic
atients and patients with heart failure.4–6 The poor prognosis
s maintained even in individuals with moderate hypona-
raemia, 130–134 mEql/l.2
Some patients with chronic kidney disease stage 5D
CKD5D), on a haemodialysis (HD), have hyponatraemia. The
ole of the kidneys in preventing hyponatraemia, tends to
isappear when residual renal function (RRF) is lost such as
n patients with CKD5D. In these patients, the sodium and
ater balance that occurs during dialysis sessions appears as new factor in the development and maintenance of hypona-
raemia.
Hyponatraemia in HD patients, as in the general popu-
ation, has been associated with a greater risk of death.7–12(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Those studies have found that low pre-haemodialysis blood
sodium levels are associated with diabetes, neurological and
psychiatric diseases, greater interdialytic weight gain (IDWG),
and greater ultraﬁltration (UF). The correlation between blood
sodium levels and mortality has been maintained, taking into
account the evolution blood sodium levels over the time.7
In HD patients, it is not clear whether the relationship
between hyponatraemia and mortality is a cause-and-effect
relationship or may be explained by some associated fac-
tor. The correlation between blood sodium levels and decline
in brain function has been clearly demonstrated.6,13 Indeed,
hyponatraemia may have a direct brain toxic effect and it
causes encephalopathy. There are situations in which the
association between hyponatraemia and mortality is even
more pronounced; such situations include cirrhosis and heart
failure, which also are common in HD patients.14 Neverthe-
less, there is no reason to believe that hyponatraemia in HD
should be equivalent l to hyponatraemia observed in the gen-
eral population.
The aim of the present study is to evaluate the rela-
tionship between serum sodium concentration and mortality
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in the Spanish HD population. It also sought to deﬁne
hyponatraemia in HD and to determine the characteristics
of hyponatraemic patients in terms of anthropometric, lab-
oratory, dialysis and body-composition measurement using
bioimpedance.
Methods
Thus is an observational, descriptive study on a cohort of inci-
dent HD patients from the Fresenius Medical Care clinics in
Spain (FME). The study was conducted from 2009 to 2012. The
following epidemiological data were evaluated: demographic
characteristics, medical history with comorbidities, dialysis
and vascular-access characteristics, laboratory data, and the
clinical course during follow-up (see list of variables of inter-
est). The independent variable was the mean value of the
pre-dialysis blood sodium concentration analysed within the
ﬁrst 6 months of HD.
Population  studied
The population included all incident HD patients in FME  clin-
ics between January 2009 and September 2012 and with at least
6 months on HD. All incident patients from January 2009 to
September 2012 registered in the Fresenius Medical Care Euro-
pean Clinical Data Base (EuCliD) database were included. The
ﬁrst date of admission recorded was 2/1/2009, and the last was
1/9/2012. All causes of loss to follow-up were recorded. These
included: functioning kidney transplant, change to periton-
eal dialysis, transferred to another centre, death (including
patients who  died in the dialysis centre, during hospitalisa-
tions or within the 3 months after being transferred), among
other causes. The patients enrolled in the study were from 63
FME  HD centres throughout Spain.
Inclusion  and  exclusion  criteria
The inclusion criteria were: incident HD patients at FME
clinics; more  than 18 years old; registered in EuCliD® (with
informed consent signed); follow-up greater than 6 months in
HD; with determination of a baseline blood sodium concen-
tration and an average blood sodium concentration from the
ﬁrst 6 months on haemodialysis.
Not having signed the informed consent form in EuCliD®
was considered to be only exclusion criteria.
EuCliD® database
The database was prepared from the data of patients included
in EuCliD®. EuCliD® is an tool developed to monitor the treat-
ment of patients from Fresenius clinics in Europe, the Middle
East, Africa and Latin America.15,16 Dialysis (both HD and per-
itoneal dialysis). Information on dialysis treatment (both HD
and peritoneal dialysis), medications received during the ses-
sions and at home, events, and comorbidities were recorded
prospectively.
This database has been used in other epidemiological
studies.17,18 An informed consent form for the use of the data
in accordance with Data Protection Agency standards was6;3  6(1):42–50
required from all the patients included in the EuCliD® registry.
Its use was described in a previous study.17
EuCliD® variables  used  in  this  study
Age at the initiation of HD, gender, time in HD, aetiology of
CKD, prior history of diabetes and heart failure, dry weight
(6-month average), height, type of HD (HD/HDF), type of vas-
cular access (VA) (arteriovenous ﬁstula or catheter), pre-HD
systolic blood pressure (SBP) (6-month average), pre-HD dia-
stolic blood pressure (DBP) (6-month average), pre-dialysis
laboratory determinations (Na, K, Cl and bicarbonate, all in
mEq/l; and blood glucose, albumin, creatinine, urea, in mg/dl),
dialysis data (UF; interdialytic weight gain (IDWG); sodium
and bicarbonate levels in the dialysis ﬂuid [DF]) and eKt/V
(6-month average). Serum sodium concentration were deter-
mined by means of indirect potentiometry.
Multi-frequency bioimpedance measurements (BCM®, Fre-
senius) were performed according to standard protocol.
Pre-dialysis weight, overhydration (OH), extracellular volume
(ECV) and intracellular volume (ICV) were collected. Rela-
tive overhydration (OH/ECV × 100) (%), ECV/ICV, percentage
of ECV (ECV × 100/pre-dialysis weight) and ICV percentage
(ICV × 100/pre-dialysis weight) were calculated. The results of
Bioimpedance analysed corresponded to the dates the labora-
tory tests.
Hyponatraemia
Hyponatraemia is considered to be a mean blood sodium con-
centration equal to or less than a mean of 136 mEq/l during the
6 months on HD. This value corresponds to the upper limit
of the lower quartile of sodium concentration in he present
study. As is observed in the results, in this lower quartile there
is a marked increase in mortality. It also corresponds to the
cut-off point adopted in other similar studies.7–12
Clinical  course
Follow-up time was considered to be the time elapsed from
the start of follow-up, enrolment in dialysis, up to the date
of exclusion. Each patient’s exclusion date was recorded as
death, transplant, transferred to another centre, discontinua-
tion of treatment, loss of follow-up, or end of the study.
Death included patients who died under the care of the
dialysis centre, during hospital admissions and patients who
were transferred and died within the following 3 months.
The causes of death were classiﬁed as: cardiovascular (CV)
death, sudden death or death at home, infections, malignan-
cies and others.
Statistics
Qualitative variables are presented as percentages, and quan-
titative variables are shown as means (±standard deviations).
Serum sodium concentration were normally distributed in
each centre. The chi-squared test was used to compare qual-
itative variables, and Student’s t-test or ANOVA was used to
compare continuous variables. Bivariate correlations between
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Table 1 – Data for patients, dialysis and laboratory tests
for the 4153 incident haemodialysis patients.
Patient Mean SD
Age (years) 64.7 15.1
Diabetes mellitus (%) 34.8
Congestive heart failure (%) 11.4
Vascular access (% ﬁstulas) 63.2
Women (%) 35.8
BMI (kg/m2) 26.4 5.2
Post-HD weight (kg) 70.2 14.7
Systolic blood pressure (mmHg) 136.2 17.6
Diastolic blood pressure (mmHg) 69.2 10.7
Dialysis Mean SD
eKt/V 1.4 0.3
HDF (%) 35.1
Sodium in dialysis ﬂuid (mEq/l) 139.1 1.2
Bicarbonate in dialysis ﬂuid (mEq/l) 34.8 1.0
Interdialytic weight gain (kg) 1.8  1.2
Total ultraﬁltration (l) 1.7 0.6
Laboratory results Mean SD
Glucose (mg/dl) 125.6 65.8
Bicarbonate (mEq/l) 22.50 3.1
Chlorine (mEq/l) 101.5 4.0
Potassium (mEq/l) 4.9 0.8
Urea (mg/dl) 122.4 35.6
Creatinine (mg/dl) 7.2 2.4
Total calcium (mg/dl) 8.9 0.6
Albumin (g/dl) 3.7 0.4
SD: standard deviation; HD: haemodialysis; HDF: haemodiaﬁltra-
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Fig. 1 – Distribution of mean blood sodium levels in thetion (on-line HDF/total HD [%]); BMI: body mass index.
erum sodium concentration and other chemistry variables
ere analysed by Pearson’s correlation coefﬁcient. Actuar-
al (Kaplan–Meier) survival curves and the log-rank test were
valuated.
Unadjusted hazard ratios (HRs) were assessed using unad-
usted hazard ratio models. Adjusted HRs were estimated by
he addition of covariates (Table 4). HRs were calculated using
ox regression individually for each variable (univariate) and
djusted to all other variables and stratiﬁed to non-diabetic
atients (multivariate). A multivariate Cox regression analysis
as performed to identify predictors of mortality, including
yponatraemia as a potential risk factor and stratifying for
he non-diabetic population. 95% conﬁdence intervals were
alculated. A p-value <0.05 was considered to be statistically
igniﬁcant. Statistical analysis was performed using SPSS ver-
ion 19 (SPSS Inc., Chicago, IL, United States) software.
esults
opulation  characteristics
 total of 4153 incident HD patients were enrolled in the
tudy. Table 1 describes their demographic characteristics.
heir mean age was 64.7 years, and men  predominated, com-
rising 64.2% of patients. Diabetics accounted for 34.8% of
atients. Caucasian accounted for 99% of patients.ﬁrst 6 months in 4153 incident HD patients.
Characteristics  of  haemodialysis  and  of  vascular  access
Table 1 describes the dialysis parameters studied. Individuals
in on-line haemodiaﬁltration (OL-HDF) accounted for 35% of
patients. Mean sodium used in the dialysate ﬂuid (DF) was
139.1 mEq/l, and mean bicarbonate level was 34.8 mEq/l.
Laboratory  monitoring
The distribution of mean serum sodium concentration for
each patient is shown in Fig. 1. The distribution was nor-
mal  or Gaussian, and the mean was 138.46 (2.70) mEq/l. Each
patient had a mean of 3.2 blood sodium level measurements
in the ﬁrst 6 months. The ﬁrst blood sodium level measured in
HD was similar to the mean, 138.58 (4.22) mEq/l, although the
dispersion of the values was greater. The quartiles of mean
blood sodium for the 6 months had the following ranges:
Q1: 135 (120–136), n = 1030; Q2: 137 (137–138), n = 1075; Q3: 139
(>138–140), n = 1011; and Q4: 141 (>140–148), n = 1037.
Table 1 lists all other laboratory results obtained. Pre-HD
blood glucose and serum albumin and creatinine correlated
with the serum sodium concentration (p < 0.0001). The corre-
lation albumin with sodium ratio disappeared in patients with
less ﬂuid overload.
Clinical  course
Mean follow-up time was 21.48 (1.31) months. At 1/03/2013,
2139 patients remained in the study. During the study 724
patients died. The main cause of loss to follow-up was kidney
transplant, accounting for 608 patients in total; 87 patients
voluntarily suspended treatment, and 595 were transferred.
Mean survival time was 3.42 (0.24) years.
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Table 2 – Mortality during follow-up, not adjusted and
expressed as a percentage, for each blood sodium
quartile.
Blood sodium quartiles n  Deaths, n (%)
Q1 1030 229 (22.20)
Q2 1075 187 (17.40)
Q3 1011 153 (15.10)
Q4 1037 155 (14.90)
Risk of death according to blood sodium quartile (not adjusted)
Sodium quartiles (blood) OR CI p
Q1 vs Q2 1.35 1.09–1.68 0.003
Q1 vs Q3 1.60 1.27–2.01 0.000
Q1 vs Q4 1.62 1.29–2.03 0.000
Hydration  stateSodium ranges by quartile: Q1 (120–136 mEq/l); Q2 (137–138 mEq/l);
Q3 (>138–140 mEq/l); and Q4 (>140–148 mEq/l).
Survival  and  blood  sodium  levels
Table 2 describes the gross mortality rate separated by quar-
tiles of serum sodium concentration. Gross mortality for
patients with low sodium levels was 22.2%, versus 14.9% for
patients with the highest sodium levels. Patients of the lower
quartile of serum sodium concentration, Q1, had signiﬁcantly
greater mortality than all other patients. The Odds ratio (OR)
between Q1 and Q4 was 1.62 (1.29–2.03). To assess whether
the highest serum sodium concentration had a worse prog-
nosis, the population was divided into deciles. Only the 3
lowest deciles had an OR > 1.5, signiﬁcant relative to the risk of
Table 3 – Clinical and laboratory variables studied according to 
haemodialysis patients.
Blood sodium
quartile range/mean
Q1
(120–136 mEq/l)
135 mEq/l
n = 1030
SD Q2
(137–138 mEq/l)
137 mEq/l
n = 1075
Age (years) 64.74 14.78 64.70 1
Women (%) 38 36 
Post-HD weight (kg) 68.1 14.16 69.9 1
Diabetes (%) 48 35 
CHF (%) 12 12 
SBP (mmHg) 137.63 18.48 135.91 1
DBP (mmHg) 68.94 11.21 69.23 1
IDWG (kg) 1.93 0.68 1.80 
UF (l) 1.89 0.67 1.77 
Glucose (mg/dl) 150.64 78.52 125.23 5
Albumin (g/dl) 3.62 0.48 3.76 
Creatinine (mg/dl) 6.83 2.47 7.06 
VA (% AVF) 59 64 
OL-HDF (%) 39 38 
eKt/V 1.4 0.49 1.4 
Sodium in dialysis
ﬂuid (mEq/l)
139.14  1.24 139.11 
Bicarbonate in dialysis
ﬂuid (mEq/l)
34.83  1.11 34.89 
Deaths (%) 22.2 17.4 
VA: vascular access; bicarbonate in dialysis ﬂuid: bicarbonate concentratio
IDWG: interdialytic weight gain; HD: haemodialysis; OL-HDF: on-line haem
signiﬁcant; SBP: systolic blood pressure; sodium in dialysis ﬂuid: sodium c6;3  6(1):42–50
death of all others deciles; the upper decile, with a mean blood
sodium level of 142.8 mEq/l, did not have an OR different from
the deciles greater than 136 mEq/l.
Table 3 describes the values of clinical and laboratory
variables in each quartile of serum sodium concentration
including the 4153 patients. The variables that showed signiﬁ-
cant differences were: post-HD weight, diabetes, systolic blood
pressure (SBP), IDWG,  UF, serum glucose, serum albumin,
serum creatinine, Vascular Access (VA) and dialysis technique.
During the ﬁrst half-year of HD, the patients who  died had
signiﬁcantly lower mean serum sodium concentration.
In the unadjusted survival curves, there were signiﬁcant
differences between the quartiles of serum sodium concentra-
tion (Fig. 2). Table 4 provides the data from the Cox regression.
It describes the variables that inﬂuenced mortality in a uni-
variate manner, with their ORs and CIs (univariate analysis),
and the multivariate analysis with variables that signiﬁcantly
predicted mortality, including the serum sodium concentra-
tion. The variables that independent predict mortality risk
were age, sex, SBP, hyponatraemia, type of VA. Heart failure,
sodium and bicarbonate concentration in the dialysate and
IDWG were not statistically signiﬁcant independent predictors
of mortality. The analysis was corrected for diabetes. There
were variables, including eKt/V, prior history of heart failure
and dialysis technique, which interact with each other.Table 5 shows the bioimpedance data in a sample smaller
than the total number of patients studied. The sample
blood sodium quartile for the 4153 incident
SD Q3
(>138–140 mEq/l)
139 mEq/l
n  = 1011
SD Q4
(>140–148 mEq/l)
141 mEq/l
n = 1037
SD p
5.42 64.22 15.34 65.03 14.98 NS
35 34 NS
5.06 70.8 14.8 72.0 15.85 0.000
31 25 <0.001
12 9 NS
8.16 135.93 16.52 135.68 17.36 0.045
0.69 69.57 10.64 69.42 10.57 NS
0.66 1.73 0.72 1.68 0.71 0.000
0.67 1.7 0.71 1.64 0.71 0.000
4.59 117.35 42.15 112.02 36.27 0.000
0.42 3.79 0.42 3.82 0.43 0.000
2.35 7.33 2.33 7.48 2.42 0.000
66 64 <0.001
34 31 0.002
0.28 1.38 0.28 1.37 0.28 NS
1.24 139.14 1.28 139.17 1.25 NS
0.92 34.82 1.01 34.89 1.2 NS
15.1 14.9 <0.001
n in dialysis ﬂuid; SD: standard deviation; AVF: arteriovenous ﬁstula;
odiaﬁltration; CHF: prior history of congestive heart failure; NS: not
oncentration in dialysis ﬂuid; total UF: total ultraﬁltration.
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Survival time (years)
At-risk 
subjects 1  2  3  4  5
Q1 697 367 152 16 0
Q2 739  432 19 8 37  0
Q3 720 439 204 22 0
Q4 709 437 210 27 0
.00 1.00 2.00 3.00 4.00 5.00
0.0
0.2
0.4
0.6
0.8
1.0
Quartiles  of serum sodium concentration—Survival functions
Q1 avg Na 135 mEq/l
Q2 avg Na 137 mEq/l
Q3 avg Na 139 mEq/l
Q4 avg Na 141 mEq/l
Q4
Q3
Q2
Q1
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Fig. 2 – (Kaplan–Meier) survival curves according to blood sodium quartile. The survival curves show the pattern of deaths
according to the sodium quartile (Q) at 6 months after entering the FMC  clinics. Mean survival time was 3.21 years (CI
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l.10–3.31) for Q1, 3.42 years (CI 3.32–3.51) for Q2, 3.51 years 
onsisted of a total of 487 patients, who had undergone at
east one bioimpedance analysis during the ﬁrst 6 months.
elative overhydration was different between blood sodium
uartiles, but differences were 1%, and there were no differ-
nces between Q1 and Q4. The LTI in patients with low blood
odium levels, Q1 (135 mEq/l) was signiﬁcantly lower than the
TI of patients from the other blood sodium quartiles.
iscussion
he main ﬁnding in this study is that patients with low blood
odium levels, less than 136 mEq/l, have a higher risk of death
han all other HD patients. This level of sodium concentra-
ion should deﬁne the hyponatraemia in HD associated to a
orse prognosis. This is valid, at least, for a broad Spanish
opulation of incident HD patients. There have been simi-
ar results in studies from other countries,7–12 with similar.42–3.60) for Q3 and 3.53 (CI 3.44–3.61) for Q4.
ranges of blood sodium concentration. In the present study,
the prognostic value of hyponatraemia in HD is indepen-
dent of other prognostic factors: age, gender, diabetes, SBP
and VA type. As described in a previous study,17 which par-
tially encompassed the same population studied here, this
is not a population with lower comorbidity than all other
Spanish dialysis patients. The factors that had an impact
on mortality in this study were the same as those identi-
ﬁed in that series,17 with the exception of hyponatraemia,
which was not studied, and those from another Spanish study
that also enrolled incident HD patients.19 In European and
American studies, those mentioned variables also appear as
predictors of mortality in HD patients.8,10–12 The relationship
between blood sodium concentration and mortality in HD
does not seem to conform to a J-curve, as occurs with other
laboratory parameters; hypernatremia does not seem to be
associated with a greater risk of death in this study or in other
studies.7–12
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Table 4 – Analysis of Cox regression (mortality).
Equation variables Univariate Multivariate
HR Sig. 95% CI HR Sig. 95% CI
Lower Upper Lower Upper
Age (years) 1.05 <0.001 1.05 1.06 1.06 <0.001 1.05 1.07
Sex (female vs male) 0.78 <0.001 0.66 0.93 1.66 <0.001 1.29 2.13
SBP (mmHg) 0.98 <0.001 0.98 0.99 0.98 <0.001 0.98 0.99
Vascular access, Cath vs AVF 2.17 <0.001 1.85 2.56 2.29 <0.001 1.81 2.89
Hyponatraemia (<136 mEq/l) 1.749 <0.001 1.43 2.13 1.98 <0.001 1.44 2.72
Diabetes mellitus 1.53 <0.001 1.3 1.8
Congestive heart failure 1.99 <0.001 1.6 2.48 1.39 >0.05 0.97 1.99
IDWG (kg) 0.84 <0.001 0.75 0.94 0.93 >0.05 0.54 1.58
Glucose (mg/dl) 1.00 <0.001 1 1.005 1.00 >0.05 0.99 1.01
Sodium/DF (mEq/l) >0.05
HDF (%) >0.05
Bicarbonate/DF (mEq/l) >0.05
eKt/V >0.05
Constant 0.01 <0.001
Cath: catheter; AVF: arteriovenous ﬁstula; IDWG: interdialytic weight gain; HDF: on-line haemodiaﬁltration; DF: dialysis ﬂuid; SBP: systolic
blood pressure. HR Cox regression, individual proportionate risk for each variable (univariate) adjusted for all other variables and stratiﬁed for
non-diabetic patients (multivariate).
In our study, the mean pre-HD serum sodium concentra-
tion analysed over 6 months was used as the main variable.
The mean pre-HD serum sodium concentration was not dif-
ferent than the baseline serum sodium concentration. It
was decided to obtain the mean pre-HD serum sodium con-
centration to avoid a potential effect of variability in the
determinations of serum sodium. In the above-mentioned
studies on HD in which blood sodium levels were associated
to mortality,7–12 the sodium level chosen as a predictive of out-
comes was the values at the time of enrolment (single value) or
mean blood sodium level (3 months or one year). This decision
was based in the assumption that each HD patient has a ﬁxed
serum sodium concentration or what has come to be called
the plasma sodium set-point.20,21 We believe that this con-
cept of a blood sodium set-point should be examined; it may
be valid in stable HD patients, but may not be entirely true
in those patients with changes in their sodium intake or in
the method of dialysis.22–24 HD patients with hyponatraemia
are those with the greatest variability in their blood sodium
determinations.23,25 In our experience and in that of Madu-
ell et al., changes in sodium intake may indeed affect blood
sodium levels in HD patients,22 as may changes in dialysis
technique.24 In the present study, to obviate this matter, it was
decided to use 6-month mean serum sodium concentrations.
Table 5 – Spectroscopic bioimpedance data for 487 HDs of the pa
n = 487 patients Q1 Q2 
Relative overhydration (%) 11.1 ± 8.9 9.8 ± 8.7 
Lean tissue index (LTI) (kg/m2) 11.2  ± 2.4 12.1 ± 2.7 
Fat tissue index (FTI) (kg/m2) 13.7 ± 6.8 15.0 ± 6.4 
ECV/weight (%) 23 22 
ECV/ICV 1.02 ± 0.14 1.01 ± 0.1
Relative overhydration OH/ECV (%). ECV: extracellular volume; ICV: int
(137–138 mEq/l); Q3 (>138–140 mEq/l); and Q4 (>140–148 mEq/l).Our study shows that serum sodium concentration was
related to age, gender, IDWG,  SBP, CHF and other variables.
All these variables are related with the body’s distribution
and content of water and sodium. The Serum sodium con-
centration, IDWG  and SBP were interrelated. Patients with
greatest IDWG  and SBP tended to have lower serum sodium
concentration. Hyponatraemia represents a pathophysiologi-
cal crossroads. First, the hyponatraemia may be caused in part
by a dilutional effect due to a large IDWG.  The fact that the
association between serum albumin and serum sodium con-
centration disappears in less overhydrated pre-HD sessions
patients speaks in favour of this dilutional effect of IDWG.
Hyponatraemia may be due to a relative increase in body
water, which may involve: cellular hyperhydration, cerebral
oedema, expansion of ECV and plasma volume, increase in
blood pressure, and cardiac overload. It has been reported
that overhydration above 15% of normal ECV involves a worse
prognosis in HD patients.26 Different prognostic factors are
SBP and IDWG.26,27 It should be noted that overhydration was
not the only cause of hyponatraemia in the HD patients stud-
ied here; there were patients with hyponatraemia with high,
normal or low hydration state. One study25 found a direct
correlation between overhydration and blood sodium levels.
Thus overhydration should be treated as a problem separated
tients and their correlation to the blood sodium quartiles.
Q3 Q4 p (ANOVA)
10.0 ± 8.2 10.8 ± 8.7 >0.05
12.2 ± 2.6 11.7 ± 2.7 0.019
13.9 ± 6.3 15.0 ± 8.4 >0.05
23 23 >0.05
3 0.99 ± 0.15 1.03 ± 0.13 >0.05
racellular volume. Blood sodium quartiles: Q1 (120–136 mEq/l); Q2
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f
d
s
a
t
H
i
n
i
i
p
r
b
l
a
h
u
w
w
t
i
T
m
p
a
t
t
f
d
e
T
p
w
c
c
b
b
t
p
o
n
a
a
I
g
h
b
m
T
a
I
d
i
p
b
ﬁ
i
r
1
1
1
1n e f r o l o g i a. 2
rom hyponatraemia. Another possibility in the differential
iagnosis of hyponatraemia is changes in body content of
odium both with and without associated osmotic changes,
lso related to changes in BP.
The kidneys play an important role in the onset and
he maintenance hyponatraemia in non-HD patients. In
D patients without residual renal function, hyponatraemia
s prevented by a reduction thirst. There are mecha-
isms that inﬂuence thirst independent of the sodium
ntake, serum sodium concentration and osmolarity. These
nclude: angiotensin II, which increases thirst and cause
olydipsia28,29; arginine vasopressin which is increased in
esponse to a reduction of ECV; increased osmolarity caused
y factors other than sodium, drugs, pain, etc.; and also
ocal oropharyngeal factors, such as dryness of the mucosae;
nd psychogenic factors.29–31 All these factors could cause
yponatraemia in HD. It was not possible to assess the resid-
al kidney function (RRF); since there were incident patients, it
as assumed that some of them started with signiﬁcant RRF,
hich may have inﬂuenced blood sodium levels. RRF in HD
ends to decrease during the ﬁrst few months and no changes
n serum sodium concentration were in the ﬁrst 6 months.
he correlation between serum sodium concentration and
ortality has been observed in oligo-anuric prevalent HD
atients.
In addition, HD may cause changes in a patient’s sodium
nd water ratio. Most sodium and water lost during HD is
hrough UF. UF causes a loss of water and sodium in propor-
ion to serum sodium concentration; the sieving coefﬁcient
or sodium is practically 1. During HD, the sodium balance by
iffusion may be substantial when there is a signiﬁcant gradi-
nt between concentration of sodium in blood and dialysate.
herefore, the concentration of sodium in the dialysate may
lay a role in this balance, in a way that is not associated with
ater loss. These changes resulting from the dialysate sodium
oncentration may inﬂuence IDWG,  BP and serum sodium
oncentration.25 In this study, we have observed a relationship
etween nutritional parameters and blood sodium levels: LTI,
ody weight and plasma creatinine and albumin concentra-
ions. There are probably 2 main types of hyponatraemic HD
atients: patients with poor nutrition and patients with ﬂuid
verload.
Hyponatraemia in HD patients is associated to poor prog-
osis. Is there any action that may correct the hyponatraemia
nd, improve the prognosis? Action can be taken on sodium
nd water intake in the diet, although this is not an easy task.
t is attempted when there is HTN or major interdialytic weight
ain. It is not common to act at this level in situations of
yponatraemia. It is technically easier to modify the sodium
alance in dialysis by modifying the total conductivity of the
achine and therefore the dialysate sodium concentration.
he dialysate sodium level tends to increase when HD toler-
nce is poor, and tends to decrease when there is HTN or major
DWG  that do not respond to increased UF and reductions of
ry weight. It is not usual to make changes in dialysate sodium
n situations of hyponatraemia. One study mentioned that the
oor prognosis associated to hyponatraemia in HD is altered
y the dialysate sodium concentration. Other studies did not
nd this correlation.9,10 All of these were observational stud-
es that are difﬁcult to interpret. Changes in dialysate sodium
13 6(1):42–50 49
determine IDWG,  BP, tolerance to dialysis and probably blood
sodium levels. Therefore, when choosing or modifying sodium
in dialysate, all these features must be assessed.
Hyponatraemia is a factor of a poor prognosis in HD
patients. Hyponatraemic patients have malnutrition or vol-
ume  overload. The aims of suitable HD should include
correcting malnutrition, volume overload and, secondarily,
hyponatraemia.
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